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Abstract: Bergamot essential oil (BEO) added to food and drink promotes a citrus flavour.
Folklore suggests benefits on gastrointestinal functions but with little supporting evidence.
BEO and major constituents (linalool, limonene, linalyl acetate) were therefore examined for
any ability to influence neuromuscular contractions of human and rat colon. Circular muscle
strips (macroscopically-normal human colon obtained following ethical approval at cancer surgery;
Sprague–Dawley rats) were suspended in baths (Krebs solution; 37 ◦C; 5% CO2 in O2) for measurement
of neuronally-mediated contractions (prevented by tetrodotoxin or atropine) evoked by electrical
field stimulation (5 Hz, 0.5 ms pulse width, 10s/minute, maximally-effective voltage), or contractions
evoked by KCl (submaximally-effective concentrations). BEO and each constituent concentration
dependently inhibited neuronally-mediated and KCl-induced contractions. In human: apparent
pIC50 for BEO (volume/volume Krebs), respectively, 3.8 ± 0.3 and 4.4 ± 0.3; Imax 55.8% ± 4.2% and
37.5% ± 4.2%. For the constituents, the rank order of potency differed in human (linalool > limonene
>> linalyl-acetate) and rat colon (linalyl-acetate > limonene = linalool), but rank order of efficacy was
similar (linalool >> (BEO) = linalyl-acetate >> limonene). Thus, linalool had high efficacy but greater
potency in human colon (Imax 76.8% ± 6.9%; pIC50 6.7 ± 0.2; n = 4) compared with rat colon (Imax 75.3%
± 1.9%; pIC50 5.8 ± 0.1; n = 4). The ability of BEO and linalool to inhibit human colon neuromuscular
contractility provides a mechanism for use as complementary treatments of intestinal disorders.
Keywords: bergamot essential oil; linalool; limonene; human; rat; colon; spasmolytic
1. Introduction
Bergamot (Citrus bergamia Risso et Poiteau) is a citrus fruit plant growing almost exclusively along
the southern coast in the area of Reggio Calabria, Italy (Regional Law 14 Oct 2002, n. 41). Since 2001,
the fruit has been given an official designation of “Protected Designation of Origin (DPO)” from the
European Union (European regulation CE n. 509/2001). The citrus has been primarily cultivated for
its essential oil, bergamot essential oil (BEO), a product in great demand by perfumery and cosmetic
industries. BEO or its constituents are also widely used by pharmaceutical, food and confectionery
industries as citrus-flavouring agents in food and drink [1].
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BEO is obtained by cold pressing of the epicarp and, partly, the mesocarp of the fresh fruit of
bergamot (Farmacopea Ufficiale Italiana, 1991). It contains several chemical classes of substances that
can be broadly separated into volatile and non-volatile fractions. The former represents 93–96% of
total volume of BEO and consists of terpens (e.g., d-limonene, β-bisabolene, γ-terpinene, α-pinene,
β-pinene, sabinene, β-myrcene, terpinolene, geranyl acetate) and oxygenated molecules (e.g., linalool,
linalyl acetate, neral, geranial, neryl acetate, geranyl acetate) [2,3]. The residual non-volatile fraction
(4–7% of total) is comprised of coumarins and psoralens such as bergamottin and citropten [2,3].
Although a large variability exists in the amount and ratio of the individual chemical constituents of the
plant, depending on botanical and cultivation factors, three monoterpenes, i.e., limonene, linalyl acetate
and linalool, are present in the largest amounts in the BEO, usually 26–53%, 16–40%, and 2–20% by
total volume, respectively [4].
The European Medicines Agency (EMA) has documented the anecdotal use of BEO [1],
which includes the facilitation of wound healing and its use as an antiseptic, anthelminthic,
antimicrobial [5] and antifungal [6] agent. BEO has also been shown to increase oxidative metabolism
in human polymorphonuclear leukocytes [7] and affect certain neuronal functions [8]. The latter
includes studies, for example, in which low concentrations of BEO were found to increase exocytosis
of excitatory amino acids in rat hippocampus, with higher concentrations stimulating the release
of glutamate through Ca2+-dependent and -independent carriers; the mechanisms of action are
unknown [9]. Further, systemic administration of BEO reduced, in a dose-dependent manner, the brain
damage caused by focal cerebral ischemia in rats, reducing the levels of the excitatory amino acid
glutamate in the penumbral region without influencing the basal amino acid levels [10]. Finally,
Rombolà et al. [11] demonstrated anxiolytic-like effects of BEO in rats, comparable with diazepam,
but without sedative-like activity.
Food and confectionery industries widely use BEO to promote a citrus flavour in food and
drink [1]. However, there is little direct evidence to indicate whether-or-not these substances can affect
gastrointestinal (GI) functions and, in particular, influence the neuromuscular activities which govern
the movements of the intestine. The possibility that such an activity might occur is supported indirectly
by the ability of BEO to influence neuronal functions elsewhere (see above) and also to directly relax
the smooth muscle in vascular preparations [12]. In one other study, linalool extracted from elsewhere
was found to inhibit contractions evoked by acetylcholine in rat isolated duodenum and ileum [13].
Thus, in the present study, it was hypothesised that BEO and perhaps certain of its major constituents
might inhibit GI neuromuscular contractility. This was examined for the first time by using human
and rat isolated colon. Previously, human isolated GI tissues have been used to study the effects of
several drugs which act directly on the GI tract to promote or inhibit GI motility, with the results
having a degree of “translational value”, in that changes in neuromuscular function correlated with
their activity in vivo [14].
A preliminary account of some of the data has previously been communicated to the European
Society of Neurogastroenterology and Motility [15].
2. Methods
2.1. Human Colon
Following ethical approval (REC 15/LO/2127), informed written consent was obtained for the
use of macroscopically normal ascending and descending/sigmoid (referred to hereon as descending)
colon obtained from patients (n = 8 females and n = 7 males, median age 61 years, ranging between
43–81 years) undergoing elective surgery for non-obstructing bowel cancer and 5–10 cm cut from
the tumour. No patient had previous chemoradiotherapy or a diagnosis of inflammatory bowel
disease. Tissue was immersed into Krebs solution (in mM: NaCl 118.3, KCl 4.7, MgSO4 1.2, KH2PO4
1.2, NaHCO3 25, D-glucose 11.1, CaCl2 2.5), pre-gassed with 95% O2 and 5% CO2, and within 2 hours
after surgery was transferred to the laboratory. The mucosa, muscularis mucosa and submucosal
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plexus were removed by blunt dissection and discarded. Muscle strips (~15 mm long and ~5 mm
wide) were cut approximately parallel to the circular muscle fibres. These were used immediately or
after overnight storage at 4 ◦C in fresh, pre-oxygenated Krebs solution.
2.2. Rat Colon
Experiments were carried out in accordance with the directives of the UK Animals (Scientific
Procedures) Act 1986 and approved by the animal welfare ethical review board for Queen Mary
University of London. All efforts were made to minimise animal suffering and to use only the number
of animals necessary to produce reliable results. Male (n = 8) and female (n = 8) Sprague–Dawley
rats weighing 150 g (Charles River Laboratories, Margate, UK) were kept in a controlled temperature
(22 ± 1 ◦C), humidity (55% ± 10%) and 12-hour light–dark cycle. Both sexes were segregated in
separate cages with food and water provided ad libitum and were used after a minimum of 6 days of
acclimatisation to their new environment following their arrival in the animal unit.
At the beginning of each experiment, the animal was killed by CO2 asphyxiation and the colon
rapidly resected and immersed in pre-oxygenated (95% O2 and 5% CO2) Krebs solution. The tissue
was cleaned of its intraluminal content, cut into opened rings (about 15 mm long and ~5 mm wide)
and used immediately. Although exposure to CO2 may adversely affect intestinal motility [16], in the
present study, the strips of colon were allowed to recover in an oxygenated, buffered solution (Krebs)
before initiating experiments; most strips responded well to EFS and KCl, and only these were used.
2.3. Tissue Bath Technique
The methods have been described in detail elsewhere [17,18]. In brief, each human or rat colon
strip was suspended between two platinum wire electrodes (15 mm in length, 10 mm apart) in 10 ml
tissue baths containing Krebs solution oxygenated with 95% O2 and 5% CO2 and maintained at
37 ◦C. Changes in muscle tension were recorded using an isometric transducer in milli-Newtons
(mN) (MLT201/D, AD Instruments, Chalgrove, United Kingdom) connected to an AcqKnowledge data
acquisition system version 3.8.1 (BIOPAC Systems Inc., Goleta, CA, USA) on a personal computer
(Dell, UK, www.dell.com/uk). The stimulation electrodes were connected to an STG2008 stimulator
(Multi Chanel Systems, Reukingen, Germany). The rat and human muscle strips were placed under
an initial load of, respectively, 10 and 20 mN, and allowed to equilibrate for 60 min (fresh tissues) or up
to 150 min (for those human tissues which were stored overnight), with renewals of the Krebs solution
every 15 min.
Electrical field stimulation (EFS) was applied with pulse trains of 5 Hz, pulse width 0.5 ms,
for 10 s every 1 min at a voltage 10% higher than that required to obtain maximal contractions [17].
Tissues were allowed to equilibrate for at least 30 (rat) or 60 (human) min, during which the basal
muscle tension and the amplitude of the phasic contractions evoked by EFS become stable. Cumulative
concentration-response curves were then obtained for BEO (10−6 to 10−3 % v/v), (-)-linalool (10−9 to
10−4 M), linalyl acetate (10−9 to 10−4 M) and (R)-(+)-limonene (10−9 to 10−4 M), with intervals of 15 min
between addition of each concentration. For linalool and limonene, the choice of isomers aligned with
the % of prevalence in BEO; ~99.5% was (−)-linalool and ~98% was (+)-limonene [2].
Changes in contraction amplitude caused by the addition of BEO or its constituents were quantified
as a percentage, by calculating the maximum reduction in the amplitude of the contractions after each
addition of the substance (determined as a mean of three consecutive contractions) and comparing with
the mean amplitude of three contractions recorded immediately before its first addition. To confirm
the neurogenic and cholinergic nature of contractions, some tissues were treated with, respectively,
tetrodotoxin (10−6 M) or atropine (10−6 M).
In other experiments, BEO and its constituents were examined for their ability to relax colon
strips pre-contracted with a submaximally-effective concentration of potassium chloride (KCl).
Preliminary studies with cumulative additions of KCl (20 to 120 mM, with 15 min intervals between
each concentration) identified the concentrations which elicited a 50% of maximal contraction (EC50
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value) as 72.1 ± 1.1 mM (n = 4) and 67.9 ± 0.9 mM (n = 3), respectively, in human (ascending and
descending) and rat (proximal and distal) colon. A submaximally-effective single concentration of
KCl was then selected (40–60 mM) to evoke a sustained tonic contraction ~ 40% of the maximum
contraction in both species, prior to constructing a cumulative concentration response curve for BEO
(10−5 to 10−3 % v/v) or linalool (10−7 to 10−4 M) at 15 min dosing intervals. To quantify the change,
the muscle tension was measured over at least 5 min prior to the application of BEO or linalool and
then again over 5 min after the addition of each concentration, once the response to that concentration
had stabilised; these were expressed as mean percentage changes.
In human colon from females and males, the amplitude of the phasic EFS-evoked contractions
was, respectively, 8.5 ± 2.1 (n = 4) and 7.8 ± 1.8 mN (n = 4) whereas the maximum sustained increase in
muscle tone caused by the submaximally-effective concentration of KCl was 22.9 ± 7.4 mN (n = 4) and
26.4 ± 7.5 (n = 3) (p > 0.05 each); the former representing approximately 33% of the latter. Similarly,
in female and male rats, the amplitude of the phasic EFS-contractions was, respectively, 7.4 ± 1.1 and
6.3 ± 1.2 mN (n = 4 each), and the sustained increase in tone generated by KCl was 6.6 ± 1.2 and 5.7 ±
0.6 mN (n = 4 each; p > 0.05 each), the former representing approximately 111% of the latter.
2.4. Materials
(−)-linalool, (R)-(+)-limonene, tetrodotoxin (TTX) and atropine were purchased from
Sigma-Aldrich, Poole, UK; linalyl acetate was purchased from Thermo Fisher Scientific, Loughborough,
UK. The “whole” BEO sample was used, as it represents the form marketed for personal human use
and for therapeutic use. BEO was kindly provided by “Capua Company1880 S.r.l.,” Campo Calabro,
Reggio Calabria (Italy) and chromatographic results on the certificate of analysis confirmed that the
essential oil contained (R)-(+)-limonene, 48.61%; linalyl acetate, 23.60%; (−)-linalool, 5.52%. BEO,
linalool, linalyl acetate and limonene were dissolved in dimethylsulphoxide (DMSO; stock solution of
10−1 M). TTX and atropine were dissolved respectively in distilled water and ethanol (stock solution
of 10−3 M). The total volume of the solvents added to the organ baths did not exceed 1% of the
bath volume.
2.5. Data Analysis
The cumulative concentration-effect curves in the absence and presence of a test substance were
fitted by non-linear regression to a four-parameter Hill equation, and the statistical significance of
any difference between unpaired data was determined by Student’s two-tailed t-test, using GraphPad
PRISM 7.0 for Windows (Graph-Pad Software, La Jolla, CA, USA). The concentration-response data
were plotted as the mean ± standard error of the mean (mean ± sem); n values are numbers of patients
or animals. p < 0.05 was considered statistically significant.
The pIC50 shows the negative logarithm of the concentration of a drug that gave a half-maximal
inhibitory response; the Imax shows the maximum inhibition obtained. Due to the difficulty of obtaining
high concentrations of ligands in solution, it was not always possible to obtain a true maximum of
activity. For this reason, apparent pIC50 and Imax values are given.
3. Results
3.1. Neuronally-Mediated Contractions
In human colon, EFS evoked a marked “after-contraction”, which occurred immediately after
termination of EFS; the increase in muscle tension generated at the peak of this contraction was 8.1 ±
1.3 mN (n = 8). In 3 of the 8 experiments, EFS also evoked a small contraction during stimulation (1.1 ±
0.1 mN); however, only the after-contraction was used for analysis since it was found in all samples
(n = 8). In the rat colon, EFS evoked monophasic contractions; the increase in muscle tension generated
at the peak of the contraction was 6.9 ± 0.9 mN (n = 8). All responses to EFS were prevented by
application of TTX 10−6 M (human: after-contractions inhibited by 97.9% ± 0.5%, n = 4; rat: contractions
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inhibited by 96.6% ± 4.2%, n = 4), consistent with the neurogenic origin of the contractions (Figure 1).
Similarly, the contractions were prevented by application of atropine 10−6 M (human: after-contractions
inhibited by 98.6% ± 0.3%, n = 4; rat: contractions inhibited by 97.2% ± 1.7%, n = 4), consistent with
the predominantly cholinergic nature of the contractions (Figure 1).
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changes in the amplitude of EFS-contractions. Each point represents the mean of patients and animals 
studied: control n = 8, TTX n = 4, ATR n = 4 in human; control n = 8, TTX n = 4, ATR n = 4 in rat. Vertical 
lines show standard error of mean. EFS (frequency 5 Hz, pulse width 0.5 ms, for 10 s every 1 min). 
EFS = electrical field stimulation. * p ≤ 0.05 versus control (t-tests). 
Time-matched vehicle controls (Figure 2) showed no statistically significant changes in the 
amplitude of EFS-evoked contractions between the beginning and end of the experiment (human: 
3.9% ± 2.7% inhibition, n = 4; rat: 5.9% ± 2.7% inhibition, n = 3; p > 0.05 each). Application of BEO to 
the human colon reduced the amplitude of EFS-evoked contractions in a concentration-dependent 
manner, the activity being consistently observed at 10−5 to 10−3 M. In these experiments, the results 
obtained using ascending and descending colon were combined (Figure 2). However, similar activity 
was observed when using either of these regions separately (Table 1). Overall, the apparent pIC50 
(volume/ volume bathing solution) was 3.8 ± 0.3, and at the highest concentration tested, the 
contractions were inhibited by 55.8% ± 4.2%. 
Application of the different constituents of BEO also caused inhibition of EFS-evoked 
contractions in human colon (Figure 2 and Table 1). The rank order of potency (apparent pIC50) was 
Figure 1. Inhibition by tetrodotoxin and atropine of EFS-evoked contractions of human and rat colon.
The representative contraction evoked by EFS before and after administration of tetrodotoxin (TTX) or
ATR is showed in panels (A) (human) and (C) (rat). Panels (B) (human) and (D) (rat) show the changes
in the amplitude of EFS-contractions. Each point represents the mean of patients and animals studied:
control n = 8, TTX n = 4, ATR n = 4 in human; control n = 8, TTX n = 4, ATR n = 4 in rat. Vertical lines
show standard error of mean. EFS (frequency 5 Hz, pulse width 0.5 ms, for 10 s every 1 min). EFS =
electrical field stimulation. * p ≤ 0.05 versus control (t-tests).
Time-matched vehicle controls (Figure 2) showed no statistically significant changes in the
amplitude of EFS-evoked contractions between the beginning and end of the experiment (human: 3.9%
± 2.7% inhibition, n = 4; rat: 5.9% ± 2.7% inhibition, n = 3; p > 0.05 each). Application of BEO to the
human colon reduced the amplitude of EFS-evoked contractions in a concentration-dependent manner,
the activity being consistently observed at 10−5 to 10−3 M. In these experiments, the results obtained
using ascending and descending colon were combined (Figure 2). However, similar activity was
observed when using either of these regions separately (Table 1). Overall, the apparent pIC50 (volume/
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volume bathing solution) was 3.8 ± 0.3, and at the highest concentration tested, the contractions were
inhibited by 55.8% ± 4.2%.
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represents the mean of patients studied: DMSO n = 4, BEO n = 5, linalool n = 4, linalyl acetate n = 4, 
limonene n = 3. The cumulative concentration-effect was determined by combining data obtained 
from both regions of colon (ascending + descending) and were fitted by non-linear regression to a 
four-parameter Hill equation. Vertical lines show standard error of mean. EFS (5 Hz, pulse width 0.5 
ms, for 10 s every 1 min). EFS = electrical field Ssimulation. * p ≤ 0.05 versus control (t-tests). 
In the rat colon, application of BEO and its constituents reduced the amplitude of EFS-evoked 
contractions in a concentration-dependent manner. Because similar activity was observed when 
Figure 2. Effect of bergamot essential oil (BEO) and its major components on EFS-evoked contractions
in human isolated colon. The examples of experimental records illustrating the pharmacology of
responses are showed in panel (A). Panel (B) shows the concentration–response curves determined by
BEO, and panel (C) shows the combination of all results obtained with linalool, linalyl acetate, limonene.
Note that the values for BEO, an oil, are given as volume/volume of bathing solution, whereas the
concentrations of the individual compounds are given as molar values. Each point represents the
mean of patients studied: DMSO n = 4, BEO n = 5, linalool n = 4, linalyl acetate n = 4, limonene n = 3.
The cumulative concentration-effect was determined by combining data obtained from both regions
of colon (ascending + descending) and were fitted by non-linear regression to a four-parameter Hill
equation. Vertical lines show standard error of mean. EFS (5 Hz, pulse width 0.5 ms, for 10 s every
1 min). EFS = electrical field Ssimulation. * p ≤ 0.05 versus control (t-tests).
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Table 1. Apparent pIC50 and apparent Imax for the inhibition of EFS-evoked contractions in human and
rat colon.
Human
Ascending Descending Ascending + Descending
Apparent
pIC50
Apparent
Imax (%)
n ApparentpIC50
Apparent
Imax (%)
n ApparentpIC50
Apparent
Imax (%)
n
Control
(DMSO) - 4.6 ± 1.4 2 - 3.2 ± 3.2 2 - 3.9 ± 2.7 4
BEO 4.7 ± 0.3 59.1 ± 6.6 2 3.1 ± 0.6 53.1 ± 11.3 3 3.8 ± 0.3 55.8 ± 4.2 * 5
linalool 6.3 ± 0.3 88.8 ± 5.4 2 6.8 ± 0.2 64.8 ± 3.2 2 6.7 ± 0.2 76.8 ± 6.9 * 4
linalyl acetate 4.7 ± 0.6 58.4 ± 0.4 2 6.3 ± 0.3 48.4 ± 0.2 2 4.4 ± 0.4 53.3 ± 2.9 * 4
limonene 5.2 ± 0.3 30.6 ± 5.3 2 5.9 21.4 1 5.5 ± 0.2 27.5 ± 4.3 * 3
Rat
Proximal Distal Proximal + Distal
Apparent
pIC50
Apparent
Imax (%) n
Apparent
pIC50
Apparent
Imax (%) n
Apparent
pIC50
Apparent
Imax (%) n
Control
(DMSO) - 6.8 ± 4.7 3 - 4.9 ± 3.5 2 - 5.9 ± 2.7
5 (3
rats)
BEO 4.2 ± 0.2 60.8 ± 3.49 * 4 4.1 ± 0.1 53.7 ± 2.4 * 4 4 ± 0.3 56.3 ± 2.2 * 8 (4rats)
linalool 5.8 ± 0.2 77.8 ± 1.3 * 4 5.8 ± 0.2 69.4 ± 3 * 4 5.8 ± 0.1 75.3 ± 1.9 * 8 (4rats)
linalyl acetate 6.8 ± 0.3 44.5 ± 2.2 * 4 7 ± 0.3 49.7 ± 3 * 4 7 ± 0.2 49.5 ± 1.7 * 8 (4rats)
limonene 5.9 ± 0.3 25.2 ± 2.1 * 4 6.4 ± 0.4 23.1 ± 2.2 * 4 6.1 ± 0.3 24.7 ± 1.5 * 8 (4rats)
Comparison of pIC50 and Imax for the inhibitory effect on EFS -mediated contractions in human and rat isolated
colon. BEO = bergamot essential oil. Note that the values for BEO are given as volume/ volume of bathing solution,
whereas the concentrations of the individual compounds are given as molar values. Data are shown separately for
each region of colon and when combined (ascending + descending, proximal + distal) and are given as means and
standard errors of the mean. * p < 0.05 shows the statistical significance between the highest concentrations of BEO
or linalool tested on EFS-contraction versus EFS-contraction control (t-tests). For the human colon, statistical tests
were carried out only for the combined data and not for the proximal and distal human colon separately as the
n-values were too small. N = number of patients or animals studied.
Application of the different constituents of BEO also caused inhibition of EFS-evoked contractions
in human colon (Figure 2 and Table 1). The rank order of potency (apparent pIC50) was linalool (6.7 ±
0.2) > limonene (5.5 ± 0.2) >> linalyl acetate-ac (4.4 ± 0.4). However, in terms of efficacy (maximum
% inhibition or apparent Imax), the rank order was linalool (76.8% ± 6.9%) >> BEO (55.8% ± 4.2%) =
linalyl acetate (53.3% ± 2.9%) >> limonene (27.5% ± 4.3%). Together, these data highlighted linalool as
the most efficacious and potent constituent of BEO.
In the rat colon, application of BEO and its constituents reduced the amplitude of EFS-evoked
contractions in a concentration-dependent manner. Because similar activity was observed when using
either proximal or distal colon (p > 0.05), the results obtained using both regions were combined.
In terms of potency the rank-order (apparent pIC50) was linalyl acetate (7 ± 0.2) > limonene (6.1 ± 0.3)
= linalool (5.8 ± 0.1). However, in terms of efficacy (apparent Imax), the rank order was linalool (75.3%
± 1.9%) >> BEO (56.3% ± 2.2%) = linalyl acetate (49.5% ± 1.7%) >> limonene (24.7% ± 1.5%) (Figure 3
and Table 1).
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Figure 3. Effect of BEO and its main components on EFS-evoked contractions in rat isolated colon.
The examples of experimental records illustrating the pharmacology of responses are shown in panel
(A) (records on left a d right show the effect obs d in proximal and distal colon, r spectively).
Panels (B–E) show the concentration–response c r es determined by BEO, linalool, linalyl acetate,
and limonene in both regions of colon. Note that the values for BEO, an oil, are given as volume/
volume of bathing solution, whereas the concentrations of the individual compounds are given as molar
values. Each point represents the mean of animals studied: DMSO n = 3, BEO n = 4 (n = 4 proximal
and n = 4 distal), linalool n = 4 (n = 4 proximal and n = 4 distal), linalyl acetate n = 4 (n = 4 proximal
and n = 4 distal), limonene n = 4 (n = 4 proximal and n = 4 distal). The cumulative concentration-effect
were fitted by non-linear regression to a four-parameter Hill equation. Vertical lines show standard
error of mean. EFS (5 Hz, pulse width 0.5 ms, for 10 s every 1 min). EFS = electrical field stimulation.
* p ≤ 0.05 shows the statistical significance between proximal (symbols in red, *) or distal (symbols in
green, *) colon versus control (t-tests). There was no difference (p > 0.05) between the data obtained
using the proximal and distal colon.
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3.2. Muscle Contractions Evoked by KCl
Unlike EFS, the submaximally-effective concentration of KCl evoked a short-lived series of phasic
contractions followed by loss of these contractions (in all preparations except the rat proximal colon)
and the development of a tonic muscle contraction sustained throughout the duration of the experiment
(Figures 4 and 5); in the presence of TTX, 1 µM the initial phasic contractions of human colon were
absent and KCl only induced a tonic contraction (data not shown). Time-matched exposure to the
vehicle did not cause a statistically significant change in the sustained contraction in either human and
rat colon Thus, comparing the contraction between the beginning and at the end of the experiment,
showed no statistically significant difference (human: 3.2% ± 3.3% inhibition, n = 4; rat: 0.9% ± 5.1%
inhibition, n = 4; Figure 4). However, in colon from both human and rat, cumulative application of
BEO or linalool caused a concentration-dependent inhibition of the contraction. In the human colon,
the maximum % inhibition of the KCl-evoked contraction (apparent Imax) caused by BEO was 37.5% ±
4.2%, with an apparent pIC50 of 4.4 ± 0.3 (Figure 4 for combined results and Table 2 for the singular
results obtained in each region of colon). Notably, at the concentrations tested, linalool appeared to
more effectively inhibit the contraction when compared with BEO, exhibiting an apparent Imax of 53.8%
± 4.6%, p < 0.0001, and an apparent pIC50 of 5.6 ± 0.4 (Figure 4 and Table 2). Similar activity was found
in ascending and descending human colon.
In the rat colon, application of BEO also reduced the KCl-evoked contraction with an apparent Imax
of 26.3% ± 3.8% and apparent pIC50 of 4.1 ± 0.5 (Figure 5). Compared with BEO, the activity of linalool
appeared more efficacious, with an overall apparent Imax = 36.1% ± 4.8%, p = 0.04 and apparent pIC50
= 5.4 ± 0.3 (Figure 5 and Table 2). Notably, however, this effect of linalool was greater in the proximal
colon (apparent Imax 47.6% ± 2.3% and apparent pIC50 was 5.6 ± 0.2; n = 4), compared with the distal colon
(apparent Imax 21.7% ± 1% and apparent pIC50 4.8 ± 0.2; n = 4; p < 0.05). No statistical difference was
observed in the apparent Imax and pIC50 of BEO between proximal and distal colon (p > 0.05).
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Figure 4. Inhibition by BEO and linalool of the contraction evoked by a submaximally-effective
concentration of KCl in human isolated colon. Panel (A) shows examples of experimental records
illustrating a cumulative concentration-response curve to KCl and the effects of vehicle, BEO and linalool
on the sustained contraction evoked by the submaximally-effective concentration of KCl. Panel (B)
shows the concentration–response curve for BEO and panel (C) shows the concentration–response
curve for linalool. Note that the values for BEO are given as volume/ volume of bathing solution,
whereas the concentrations of linalool are given as molar values. Each point represents the mean of
patients studied: BEO n = 4 and linalool n = 4. The cumulative concentration-effect was determined
by combined data obtained of both regions of colon (ascending + descending) and were fitted by
non-linear regression to a three or four-parameter Hill equation. Vertical lines show mean ± sem.
* p ≤ 0.05 versus control (t-tests).
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Figure 5. Inhibition by BEO and linalool of the contraction evoked by a submaximally-effective
concentration of KCl in rat isolated colon. Panel (A) shows examples of experimental records (records
on left and right show the effect observed in proximal and distal colon, respectively) illustrating
a cumulative concentration-response curve to KCl and the effects of vehicle, BEO and linalool on the
sustained contraction evoked by the submaximally-effective concentration of KCl. Panel (B) shows
the concentration–response curve for BEO and panel (C) shows the concentration–response curve for
linalool in both regions of colon. Note that the values for BEO are given as volume/ volume of bathing
solution, whereas the concentrations of linalool are given as molar values. Each point represents the
mean of animals studied: BEO n = 4 (n = 4 proximal and n = 4 distal) and linalool n = 4 (n = 4 proximal
and n = 4 distal). The cumulative concentration effect was fitted by non-linear regression to a three
or four-parameter Hill equation. Vertical lines show mean ± sem. * p ≤ 0.05 shows the statistical
significance between proximal (symbols in red, *) or distal (symbols in green, *) colon versus control
(t-tests). † p < 0.05 shows the statistical significance between the inhibition produced in proximal and
distal colon (t-tests).
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Table 2. Apparent pIC50 and apparent Imax for the inhibition of KCl-evoked contractions in human and
rat colon.
Human
Ascending Descending Ascending + Descending
Apparent
pIC50
Apparent
Imax (%)
n ApparentpIC50
Apparent
Imax (%)
n ApparentpIC50
Apparent
Imax (%)
n
Control
(40–60 mM
KCl)
- 6.41 ± 6.3 2 - 0.2 ± 0.1 2 - 3.2 ± 3.3 4
BEO 4.4 ± 0.8 38.8 ± 19.6 2 4.5 ± 0.2 36.1 ± 2.9 2 4.4 ± 0.3 37.5 ± 4.2 * 4
linalool 5.3 ± 0.2 58.9 ± 4.3 2 5.9 ± 0.5 52.3 ± 4.2 2 5.6 ± 0.4 53.8 ± 4.6 * 4
Rat
Proximal Distal Proximal + Distal
Apparent
pIC50
Apparent
Imax (%)
n ApparentpIC50
Apparent
Imax (%)
n ApparentpIC50
Apparent
Imax (%)
n
Control
(40–60 mM
KCl)
- 1.4 ± 0.73 4 - 0.6 ± 5.6 4 - 0.9 ± 5.1 8 (4rats)
BEO 4.4 ± 0.4 32.8 ± 3.2 * 4 3.7 ± 0.4 19.9 ± 5.5 * 4 4.1 ± 0.5 26.3 ± 3.8 * 8 (4rats)
linalool 5.6 ± 0.2 47.6 ± 2.3 *,† 4 4.8 ± 0.2 21.7 ± 1 * 4 5.4 ± 0.3 36.1 ± 4.8 * 8 (4rats)
Comparison of pIC50 and Imax for the inhibition effect on KCl-mediated contractions in human and rat isolated
colon. BEO = bergamot essential oil. Note that the values for BEO are given as volume/volume of bathing solution,
whereas the concentrations of the individual compounds are given as molar values. Data are shown separately
for each region of colon and when combined (ascending + descending, proximal + distal) and are given as means
and standard errors of the mean. * p < 0.05 shows the statistical significance between the highest concentrations of
BEO or linalool tested on KCl-contraction versus KCl-contraction control (t-tests); † p < 0.05 shows the statistical
significance between the inhibition produced in proximal and distal colon (t-tests). For the human colon, statistical
tests were carried out only for the combined data and not for the ascending and descending colon separately as the
n-values were too small. N = number of patients and animals studied except when data from rat proximal and
distal colon are combined (usually from the same animal), when N = number of tissues studied.
4. Discussion
The present study demonstrates, for the first time, the ability of BEO and more, especially linalool,
a constituent of BEO, to inhibit cholinergically-mediated contractions of human colon evoked by
EFS. Broadly similar activity was also observed when using EFS to evoke cholinergically-mediated
contractions of rat isolated colon. Nevertheless, small differences suggested species differences in
mechanisms of action. Thus, in the human colon, linalool was the most potent (apparent pIC50 6.7)
and effective (maximum of 76.8% inhibition) inhibitor of neuromuscular function, and whilst linalool
remained the most efficacious inhibitor of neuromuscular function in the rat colon (maximum of 75.3%
inhibition), the potency of linalyl acetate (apparent pIC50 7; maximum inhibition of 49.5 %) was greater
(linalool apparent pIC50 5.8).
The application of BEO or linalool also relaxed the muscle of human and rat colon when contracted
in a sustained manner by KCl added to the bathing solution. Such a procedure is normally considered
to cause contraction of GI preparations largely by depolarization of the smooth muscle with the
consequent opening of L-type calcium channels and a rise in intracellular (Ca2+) leading to muscle
contraction [19,20]. However, a limitation of the present study is that KCl will also depolarize the
intrinsic neurons of the colon. For this reason, BEO and linalool were added only after fade of the
initial phasic contractions following the application of KCl and replacement by the tonic muscle
contraction that was sustained over 60–90 min. Thus, the ability of BEO and linalool (when tested
separately) to inhibit the contraction induced by KCl suggests a direct action on the smooth muscle
cells. In this activity, the potency of BEO and its constituents appeared to be less than that measured
when tested against the EFS-evoked contractions. However, it is difficult to know with any certainty
if such differences reflect the differences in types of assay (e.g., measurement of phasic versus tonic
contraction) or if this indicates an additional ability of these substances to directly inhibit neuronal
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functions. Further experiments in both species are needed to examine the actions of BEO and linalool
on KCl-induced contractions in the presence of TTX.
Linalool is a constituent of essential oils that are often found in plants with characteristic aroma
and flavour [21]. When isolated, linalool has been shown to cause smooth muscle relaxation in
animal tissues, including guinea-pig ileum (from lavender; Lavandula angustifolia P. Miller) [22] and
rat intestine (from South American chemotypes of Lippia alba) [13]. In addition, BEO has been shown
to cause vasorelaxation of mouse aorta [12], inducing hyperpolarization by activation of potassium
channels, an effect partially inhibited by the K+ channel blocker tetraethylammonium chloride. In these
experiments, the CaCl2-induced contraction of the mouse aorta was also inhibited by pre-treatment
with BEO, highlighting a direct or indirect ability to block cell membrane calcium channel functions [12].
Thus, from the literature, it may be speculated that BEO or linalool (when tested separately) may
inhibit muscle contractility in rat and human colon by acting on voltage-gated calcium channels present
on myocyte membranes, reducing intracellular availability of Ca2+. Nevertheless, regardless of the
mechanism of action at the smooth muscle, an additional ability to directly inhibit neuronal function
cannot be excluded.
In different animal models of non-GI activity, BEO has been shown to modulate synaptic function
in both physiological and pathological conditions [9–11]. Anti-nociceptive activities of BEO and
linalool (isolated from various sources) have also been well documented [23]. Vatanparast et al. [24]
suggested that the inhibitory action of linalool (10−4 M) in central neurons of Caucotachea atrolabiata was
exerted mainly via voltage-gated sodium channels, reducing the probability of generating an action
potential [24]. Another study, which investigated the effects of linalool on various voltage-gated
currents in rat sensory neurons, demonstrated that linalool (3 × 10−3 M) was a more effective inhibitor
of Na+ current (IC50 5.6 × 10−4 M) compared with other currents [25]. Thus, in summary, we can
understand that BEO, acting mainly through the actions of linalool, could act at smooth muscle
and/ or neuronal cells by influencing Na+, Ca2+ and/ or K+ intracellular levels [12,24,25]. In muscle
cells, linalool may block the membrane voltage-gated calcium channels, reducing intracellular [Ca2+]
and causing muscle relaxation by reducing the interaction between actin and myosin filaments [26].
In nerve cells, an action of linalool on voltage-dependent sodium channels [24,25] would reduce the
probability of generating action potentials, preventing the increase in intracellular Ca2+ required to
guarantee fusion of synaptic vesicles on the presynaptic membrane, resulting in inhibition of the
release of neurotransmitters, including acetylcholine.
It should be noted that linalool (IC50 1.41 × 10−4 M) has also been shown to block 5-HT3 receptor
activity (a ligand-gated ion channel) in a non-competitive, non-surmountable manner [27]. Further,
high concentrations activate the human (10−4 M) or mouse (6.7 ± 2.0 × 10−3 M) TRPM8 receptor [28,29]
and induce a transient increase in short circuit current in mouse isolated duodenum but not colon
mucosa (10−4 and 3 × 10−4 M) [30].
5. Conclusions
The results obtained confirm the hypothesis that BEO, largely through the actions of linalool,
can inhibit cholinergically-mediated contractions of the human colon, at least partly by acting directly
to relax smooth muscle contractility. This activity of BEO must be due to a combination of the effects
of the different constituent, but of these, it must be noted that although likely to be present in small
amounts, linalool was the most efficacious and most potent. The ability of BEO and its constituents to
inhibit neuronally-mediated contractions were similar in the rat colon, although compared with the
human colon, the constituents exhibited differences in potency.
Consequently, the present study supports the use of BEO to promote “gastrointestinal health”,
demonstrating a mechanism by which BEO may have potential benefits in the complementary treatment
of intestinal diseases related to increased muscle movement. In such patients, muscle relaxants such
as the L-type calcium channel blocker pinavarium are, for example, prescribed for treatment of
irritable bowel syndrome [31]. Clearly, further studies are needed to clarify the still poorly understood
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mechanisms of action of BEO and, in particular, demonstrate translation of the present findings by
studies in vivo, looking for potential spasmolytic activity in addition to the necessary safety studies.
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